AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

LGND · NASDAQ · Biotechnology

Ligand Pharmaceuticals (LGND)

Builds biopharmaceutical royalty portfolios and licenses Captisol and NITRICIL drug technologies.

$300.34

vs last close+1.84 (+0.62%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	33	28	31	42	52	43	45	48	115	60	52	64
Cost of revenue	3	2	11	−15	12	3	5	3	25	−26	2	3
Gross profit	29	26	20	57	39	40	40	45	91	86	50	60
	26	30	17	76	36	50	77	36	36	66	32	52
Research & development	6	5	6	5	6	4	50	7	21	4	2	15
	15	16	11	18	24	26	19	20	28	25	21	29
General & administrative	15	16	11	18	24	26	19	20	28	25	21	29
Other expenses	6	8	0	53	6	20	8	10	−14	37	9	8
Operating income	3	−3	3	−19	3	−10	−36	8	55	20	17	9
	−15	20	110	−46	−9	−30	−14	3	86	37	−42	56
Interest income	2	2	2	3	1	2	2	2	4	6	7	7
Interest expense	0	0	0	1	1	1	1	1	1	2	2	2
Other non-operating income	15	−21	−111	45	9	29	13	−4	−86	−37	40	−56
Income before tax	−12	17	113	−65	−6	−39	−50	11	141	57	−24	64
Income tax expense	−2	−1	27	−13	1	−8	−8	6	24	12	−11	16
Net income from continuing operations	−10	18	86	−52	−7	−31	−42	5	117	45	−13	49
Net income	−10	18	86	−52	−7	−31	−42	5	117	45	−13	49
EPS, basic	−$0.74	$1.04	$4.86	−$2.88	−$0.39	−$1.64	−$2.21	$0.25	$5.99	$2.27	−$0.67	$2.42
EPS, diluted	−$0.74	$1.03	$4.75	−$2.88	−$0.39	−$1.64	−$2.21	$0.24	$5.68	$2.12	−$0.67	$2.22
Weighted average shares, basic	17	17	18	18	18	19	19	19	19	20	20	20
Weighted average shares, diluted	17	18	18	18	18	19	19	20	20	21	20	22
EBITDA	−4	26	122	−55	3	−30	−41	21	149	66	−14	72
Depreciation & amortization	9	9	9	9	9	9	9	9	8	10	8	8
EBIT	−12	17	114	−64	−6	−38	−49	12	141	57	−23	64